Stephen P. Salloway Professor of Neurology, Professor of Psychiatry and Human Behavior

Stephen Salloway, MD, MS, is Director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, and Professor of Clinical Neurosciences and Psychiatry at Brown Medical School. He is the Director of the Brown Combined Residency in Neurology and Psychiatry and Codirector of the National Institute on Aging-sponsored Brown Dementia Research Fellowship Program. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.

Dr. Salloway has published more than 185 scientific articles, book chapters, and abstracts and has edited 3 books. His research focuses on the following areas: clinical trials for the prevention and treatment of Alzheimer's disease, mild cognitive impairment, and vascular dementia; studies of genetic and sporadic forms of microvascular brain disease; studies of executive function and frontal behaviors; and the development of imaging biomarkers to study conversion to dementia. Dr. Salloway has received numerous grants for his research from the National Institutes of Health and from private foundations. He published the first controlled clinical trials of cholinesterase inhibitors for the treatment of mild cognitive impairment and vascular dementia. Under his direction, the Butler Memory and Aging Program has become a nationally recognized clinical research center that tests new disease-modifying treatments for Alzheimer's disease, including amyloid vaccines, gamma secretase inhibitors and modulators, antifibrillization agents, and RAGE inhibitors. His program has also become a key research center in the United States for the study of CADASIL, a genetic disorder that causes stroke and vascular dementia.

Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations. Dr. Salloway lectures widely on dementia and he is a leading proponent of the early diagnosis and treatment of Alzheimer's disease.

Brown Affiliations

Research Areas

research overview

My research focuses on the following areas: clinical trials for the prevention and treatment of Alzheimer's disease, mild cognitive impairment, and vascular dementia; studies of genetic and sporadic forms of microvascular brain disease; studies of executive function and frontal behaviors; and the development of imaging biomarkers to study conversion to dementia.

funded research

1. Sleep patterns in people over age 75
National Institute on Aging
$15,000.
1982 – 1983
Role: Principal investigator.
2. A trial of gamma knife anterior capsulotomy to treat refractory obsessive compulsive disorder. A collaborative trial by Brown University, Massachusetts General Hospital and the Karolinska Institute. Jenike M, Rasmussen S. Principal Investigators
1992-present
Role: Investigator assisting with neurological assessment and quantitative imaging analysis.
3. Imitrex post-marketing surveillance study: a multi-center study
Glaxo Pharmaceuticals S2B-350
1994-5
Role: Investigator
4. A multi-center, randomized double-blind, comparative study of gabapentin administered as an initial dosage of 900 mg/day versus a dosage titrated to 900 mg/day over three days.
Parke-Davis Pharmaceuticals 945-090
$3,610.
1994-5
Role: Investigator
5. Subcortical vascular disease in aging
Neurology Foundation Faculty Development Fund
$18,000.
1994-5
Role: Principal Investigator
6. Quantitative MRI analysis of subcortical white matter changes in late-life onset depression
Brown University Department of Psychiatry and Human Behavior Pilot Project Grant.
1992-3-$30,000.
1994-5-$16,000.
Role: Principal Investigator
7. Longitudinal course of subcortical cerebrovascular disease in late-life depression: an MRI follow-up study. Jenkins M-PI
Butler Hospital Faculty Research Fund
$25,000.
1995-6
Role: Co-investigator
8. Subcortical vascular disease in geriatric hypertension
Surdna Foundation Fellowship for Research in Gerontology
$15,000.
1995-6
Role: Principal Investigator
9. Cognex: neuropsychiatric testing and assessment of caregiver time
Parke-Davis Pharmaceuticals 970-87
$2,000
1996-7
Role: Investigator
10. Vascular predictors of depression and cognitive impairment in the elderly.
Brown University, Dept. of Psychiatry and Human Behavior Pilot Project Grant
$20,000
1996-7
Principal Investigator
11. Effect of pemoline on measures of attentional performance in adult ADHD
Abbott Laboratories
$4,000
1996-7
Principal Investigator
12. An open-label trial of donepezil for the treatment of Alzheimer's disease
Pfizer/Esai Pharmaceuticals E2020-A001-313
$22,500
1996-7
Co-Principal Investigator
13. Neuropathological, neuroimaging and neuropsychological features of CADASIL.
American Heart Association Grant-in-Aid 9706211S
$20,000
1997-9
Principal Investigator
14. An eight-week, parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with DSM-IV major depression. Martin Keller-PI
Pfizer Pharmaceuticals R-0552
$71,000
1997-8
Brown site administrator, Co-investigator
15. Relationship of MRI hyperintensities to treatment response in geriatric depression.
Pfizer Pharmaceuticals R-0552 MRI study
$150,000
1997-2000
Principal Investigator with Ranga Krishnan, M.D. of Duke for this multi-center study
16. Metrifonate Nationwide Investigational Trial
Bayer Pharmaceuticals D-97-019
$10,000
1997-8
Principal Investigator
17. A 24 week, multi-center, randomized, double-blind, placebo-controlled evaluation of
the efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease. Eisai Inc. E2020-A001-307
$ 130,000
1998-2001
Principal Investigator, Brown site
18. A multi-center, double-blind comparison of efficacy and safety of Seroquel, haloperidol, and placebo in the treatment of elderly subjects residing in nursing homes or assisted care facilities and Presenting with Alzheimer's dementia and psychoses or other selected psychoses.
Zeneca Pharmaceuticals 5077IL/0039
$120,000
1998-9
Investigator and administrator of the Brown site
19. A randomized, double-blind, placebo-controlled trial of citalopram in depressed patients at least 75 years of age.
Forest Laboratories CIT-MD3-97-03-000
$130,000
1998-
Investigator, Brown site administrator
20. Subcortical microvascular disease in geriatric depression
National Institute of Mental Health 1 K08 MH01487
$752,994
1999-2004
Principal Investigator
21. A 24-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment.
Eisai E2020-A001-401
$110,000
1999-2000
Co-Principal Investigator with Paul Malloy, Ph.D.
22. A multi-center, randomized, double-blind, placebo-controlled trial of estrogen to prevent Alzheimer's disease in women at risk.
National Institute on Aging RO 1AG15922/Columbia University
$146,000
1999-2003
Principal investigator, Brown site
23. Combined behavioral and pharmacological intervention to improve memory in Alzheimer's disease
Alzheimer's Association Investigator Award (Deborah Cahn-Weiner PI)
$80,000
1999-2001
Consultant
24. Improving sleep and cognitive functioning in Alzheimer's disease
Eisai/Pfizer Investigator Award (Mark Aloia PI)
$100,000
1999-2001
Investigator
25. Genetic Models of Human Dementia
P20 RR15578-01 (a project of the Brown Center for Genetics and Genomics COBRE total grant $11,219,863)
$1,013,374
2000-2005
Co-Principal Investigator (Justin Fallon, subproject PI)
26. Heart Disease, CNS Dysfunction and Outcome in the Elderly
NIH 1050258905
$1,753,134 (Ronald Cohen, PI)
2000-2005
Investigator
27. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment clinically at risk for development of clinically probable Alzheimer's disease.
Janssen GAL-INT-11
$300,000
2001-4
Principal Investigator
28. A randomized, 30-week. double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease
Janssen Research Foundation GAL-INT-26
$125,000
2001-3
Principal Investigator
29. Functional impairment in Alzheimer's disease and normal aging
National Institute on Aging
AG05898-01 (Patricia Boyle, PI)
$60,000
2000-2
Consultant/Investigator
30. Treatment of apathy in Alzheimer's disease
Alzheimer's Association, (Patricia Boyle, PI)
$100,000
2001-3
Consultant/Investigator
31. Electrical stimulation of the internal capsule for intractable OCD and depression (Ben Greenberg, P.I.)
Medtronics
2001-present
Investigator assisting with neurological assessment and quantitative imaging analysis
32. A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and GI tolerance in patients with mild-moderate Alzheimer's disease
Janssen Pharmaceutica
$100,000
2002-
Principal Investigator
33. A telephone intervention for dementia caregivers
NIMH R21 MH62561, (Geoffrey Tremont, PI)
$576,042
2002-5
Consultant/Investigator
34. An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease (Protocol # A2581078)
Pfizer, Inc.
2003-5
$274,240
Principal Investigator
35. NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI)
$1,492,665
2003-2008
Description: Dementia research fellowship for 2, 2-year post-docs in 2003 increasing to 4 2-year positions.
co-PI with Richard Besdine
36. A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-319)
Eisai Medical Research, Inc.
2003-
$81,336
Principal Investigator
37. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of Titration and Treatment with C105 in Subjects with Mild Cognitive Impairment (MCI) (Protocol # 22020)
Sention Inc.
2003
$157,400
Co-Principal Investigator
38. Efficacy and Safety of LY451395 in Patients with Probable Alzheimer's Disease
(Protocol #H6N-MC-LEAM)
Lilly Pharmaceuticals
2003
$101,856
Principal Investigator
39. Working memory and frontal white matter integrity in mild cognitive impairment
Alzheimer's Association (Stephen Correia, Ph.D., PI)
NIRG-03-6195
2003-5
$100,000
Mentor and investigator
40. An open-label, multi-center, one-year extension of the evaluation of donepezil hydrochloride (E2020, Aricept®) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-320)
Eisai Medical Research, Inc.
2003-2005
$62,964
Principal Investigator
41. A 51 week, , multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment (Protocol # E2020-A001-412)
Eisai Medical Research, Inc.
2004-
$128,832
Principal Investigator
42. Galantamine ER open label rapid dose escalation trial in Alzheimer's disease
(Protocol # GAL-ALZ-303)
Janssen Pharmaceutica Products, L.P.
2004-2005
$32,000
Principal Investigator
43. A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease (Protocol ONO-2506POU010)
Ono Pharmaceutical Co., Ltd.
2004-
$214,890
Principal Investigator
44. A phase III study of the efficacy and safety of Alzhemed™ in patients in mild to moderate Alzheimer's disease (Protocol CL-758007)
Neurochem, Inc.
2004-
$462,000
Principal Investigator
45. An open-label, 8-week clinical trial of the safety and efficacy of Escitalopram for the treatment of depression and anxiety in dementia caregivers
Forest Laboratories
2005-
$106,111
Principal Investigator
46. Aging Brain: DTI, Subcortical Ischemia and Behavior
1 R03 AG023916-01A1
2005-2007
$120,000
Principal Investigator
47. Metrics for Quantifying White Matter Variation: Image Analysis, Testing and Application
Brown Vice-President Seed Grant
2005-6
$100,000
David Laidlaw, PI (Co-Investigator)
48. Treatment of apathy in Alzheimer's disease with modafinil
1 F32 MH075583-01
2005-2007
Laura Frakey, Ph.D., PI, (co-mentor with Dr. Malloy)
49. Phase 3 Multi Center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type (MPC-7869-04-005.03)
Myriad Pharmaceuticals, Inc.
2005-
$161,772
Principal Investigator
50. A Phase IIa Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 (ELN116727) in Patients with Mild to Moderate Alzheimer's Disease (AAB-001-210)
Elan Pharmaceuticals, Inc
2005-
$196,482
Principal Investigator
51. A Phase I, Multicenter, Randomized, Blinded, Single Ascending Dose, Safety, and Tolerability Trial of ACC-001 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease (ACC-001-10)
Elan Pharmaceuticals, Inc
2005-
$181,454
Principal Investigator
52. A Double-Blind Placebo-Controlled Study of VP4896 For The Treatment Of Mild-To-Moderate Alzheimer's Disease (VP-AD-301)
Voyager Pharmaceutical Corporation
2005-
$276,000
Principal Investigator
53. Alzheimer's Disease Neuroimaging Initiative ADNI-024
NIA U01 AG10483
2006-
$330,825
Principal Investigator
54. An 18 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
Eisai
2005-6
$160,000
Principal Investigator, Steering Committee Member, assisted with study design
55. A 54' week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APO €4-stratified subjects with mild to moderate Alzheimer's disease
Glaxo Smith Kline
2006-
$250,000
Principal Investigator
56. Inter-rater reliability between expert and non-expert-physicians in the diagnosis of amnestic MCI in the community setting A2501051/E0000-A001-001
Pfizer, Eisai
2006-
$23,000
Principal Investigator, Consensus Committee Member
57. A phase IIa, multicenter, randomized multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 with QS-21 adjuvant (amyloid vaccine trial) in patients with mild to moderate Alzheimer's Disease
Wyeth ACC-001 3134K1-2201
2007-present
$790,649
Principal Investigator
58. Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease
Eisai
2007-present
$140,000
Principal Investigator